ENTRY       D12632                      Drug
NAME        Beremagene geperpavec (USAN/INN);
            Vyjuvek (TN)
PRODUCT     VYJUVEK (Krystal Biotech)
REMARK      Product: D12632<US>
EFFICACY    Dystrophic epidermolysis bullosa treatment
  DISEASE   Dystrophic epidermolysis bullosa (COL7A1 mutation) [DS:H00587]
  TYPE      Gene therapy product
COMMENT     Treatment of epidermolysis bullosa dystrophica
TARGET      COL7A1 [HSA:1294] [KO:K16628]
  PATHWAY   hsa04974(1294)  Protein digestion and absorption
BRITE       Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Organismal systems
               Digestive system
                COL7A1
                 D12632  Beremagene geperpavec (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             Cellular and gene therapy products
              D12632
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12632
DBLINKS     CAS: 2241888-62-8
///
